IPP Bureau

Pradhan Mantri Bhartiya Janaushadhi Pariyojana achieves sales worth Rs. 1,000 croe in Oct. 2024
Pradhan Mantri Bhartiya Janaushadhi Pariyojana achieves sales worth Rs. 1,000 croe in Oct. 2024

By IPP Bureau - October 22, 2024

Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups

Mastek partners Innovaccer to transform value-based care and improve patient experience
Mastek partners Innovaccer to transform value-based care and improve patient experience

By IPP Bureau - October 22, 2024

This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences

KIMS signs MoU with Wipro GE Healthcare valuing upto Rs. 700 Cr
KIMS signs MoU with Wipro GE Healthcare valuing upto Rs. 700 Cr

By IPP Bureau - October 21, 2024

Health Minister Nadda inaugurates Medicine Update BJMFCON 2024
Health Minister Nadda inaugurates Medicine Update BJMFCON 2024

By IPP Bureau - October 21, 2024

Infant Mortality Rate in Bihar came down from 42 to 27 in 2020, and in Jharkhand, from 34 to 25 in 2020

Senores Pharmaceuticals gets SEBI nod for IPO
Senores Pharmaceuticals gets SEBI nod for IPO

By IPP Bureau - October 21, 2024

The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements

Sunbird Bio raises additional US $14 million to advance Alzheimer blood tech test
Sunbird Bio raises additional US $14 million to advance Alzheimer blood tech test

By IPP Bureau - October 21, 2024

Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI

PM Modi inaugurates Rs. 110 crore R Jhunjhunwala Sankara Eye Hospital in Varanasi
PM Modi inaugurates Rs. 110 crore R Jhunjhunwala Sankara Eye Hospital in Varanasi

By IPP Bureau - October 21, 2024

Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections

JB Pharma outlines key ESG goals & targets in Third Sustainability Report FY24
JB Pharma outlines key ESG goals & targets in Third Sustainability Report FY24

By IPP Bureau - October 21, 2024

JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%

Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules
Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules

By IPP Bureau - October 21, 2024

Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension

Zydus receives final approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 mg
Zydus receives final approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 mg

By IPP Bureau - October 19, 2024

Fludrocortisone acetate tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad

Granules India receives ANDA approval for Bupropion Hydrochloride ER Tablets
Granules India receives ANDA approval for Bupropion Hydrochloride ER Tablets

By IPP Bureau - October 19, 2024

Granules now has a total of 67 ANDA approvals from the USFDA

Roche’s Vabysmo improved vision in underrepresented populations with DME in a first-of-its-kind study
Roche’s Vabysmo improved vision in underrepresented populations with DME in a first-of-its-kind study

By IPP Bureau - October 19, 2024

Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies

Long-term efficacy and safety profile of Eylea 8 mg with extended dosing intervals in diabetic macular edema confirmed at three years
Long-term efficacy and safety profile of Eylea 8 mg with extended dosing intervals in diabetic macular edema confirmed at three years

By IPP Bureau - October 19, 2024

Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years

Gland Pharma appoints Shyamakant Giri as CEO
Gland Pharma appoints Shyamakant Giri as CEO

By IPP Bureau - October 19, 2024

Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals

AstraZeneca advances science of infectious disease protection at IDWeek 2024
AstraZeneca advances science of infectious disease protection at IDWeek 2024

By IPP Bureau - October 18, 2024

Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19

Latest Stories

Interviews

Packaging